

PHARMACIST-LED INTERVENTIONS TO PREVENT OPIOID MISUSE

PATEL AYUSHI SHAILESHBHAI ¹, MEHTA HIRALBEN SATISHCHANDRA^{2,*}

¹Research Scholar, Parul Institute of Pharmacy and Research, Parul University Limda, Vadodara 391760, Gujarat, India

^{2*}Assistant Professor, Parul Institute of Pharmacy and Research, Parul University Limda, Vadodara 391760, Gujarat, India

*Address for correspondence: Department of Quality Assurance, Parul Institute of Pharmacy and Research, Parul University, Vadodara, Gujarat, India.

E-mail: hiralben.mehta29533@paruluniversity.ac.in

Tel: +919033388478

DOI: <https://doi.org/10.63001/tbs.2025.v20.i01.pp180-185>

KEYWORDS

Opioid Crisis, Pharmacist, Opioid Stewardship, Public Health, Overdose prevention, Pharmacist-led interventions

Received on:

12-11-2024

Accepted on:

10-12-2024

Published on:

24-01-2025

ABSTRACT

The opioid epidemic continues to be a major public health challenge worldwide, characterized by escalating rates of misuse, dependency, and overdose-related mortality. Pharmacists, as accessible and highly trusted healthcare professionals, are strategically positioned to play a pivotal role in mitigating opioid misuse and its associated consequences. However, pharmacists face several challenges in implementing these interventions effectively. Regulatory barriers, such as restrictions on prescribing naloxone or providing medication-assisted treatment, can limit their scope of practice. Resource limitations, including insufficient funding and lack of access to advanced tools like Prescription Drug Monitoring Programs (PDMPs), further hinder their efforts. Additionally, inadequate specialized training in opioid safety and stigma associated with harm reduction measures remain significant obstacles. Looking ahead, expanded pharmacist training programs and integration into multidisciplinary teams could enhance their impact. Digital health technologies, including telepharmacy and advanced PDMP tools, offer promising avenues to streamline efforts. Furthermore, fostering collaboration with public health organizations and policymakers can help pharmacists secure the resources and authority necessary to implement these strategies at scale. This Article will also showcase case studies and examples of successful pharmacist-led interventions to provide practical insights into overcoming these challenges and achieving measurable outcomes in opioid misuse prevention.

INTRODUCTION

The opioid epidemic, which is marked by rising rates of abuse, dependence, and overdose-related deaths, remains a significant global public health concern. It is a worldwide problem that some opioids, including heroin, morphine, codeine, fentanyl, methadone, and tramadol, can be abused due to their euphoric effects (Adams et al., 2024).

The UNODC's World Drug Report 2022, which was made public on Monday, estimates that 284 million individuals between the ages of 15 and 64 used drugs globally in 2020, a 26% increase from the decade before. The abuse of opioids has become a serious public health emergency with wide-ranging social and financial ramifications. Addiction, overdose, and death rates have increased globally as a result of the improper use of opioids, whether through overprescription, diversion, or misuse (Cid et al., 2023). Effective interventions are urgently needed, as opioid overdoses caused over 80,000 deaths in the United States alone in 2021 (CDC, 2022). Because of their crucial role in medication management, pharmacists are in a unique position to put policies in place that reduce opioid abuse (Adams et al., 2024; Ardeljan et al., 2020).

Prescription monitoring, patient education, and following evidence-based prescribing guidelines are just a few of the many activities that fall under the broad category of pharmacist-led interventions (Ducharme et al., 2024; Frimerman, 2020). These programs seek to minimize the risks of overdose and dependency while ensuring that opioids are used appropriately. By giving patients and medical professionals vital information regarding the advantages and disadvantages of opioid therapy, pharmacists can also act as educators (Friedman, 2024). The efficacy of opioid stewardship initiatives is further increased by their active involvement in Prescription Drug Monitoring Programs (PDMPs) and cooperation with other medical specialists (Hughes et al., 2024; Offu et al., 2024). The implementation, results, and potential to address this ongoing crisis are the main topics of this paper's exploration of the various pharmacist-led strategies aimed at preventing opioid misuse.

EXAMINING HEALTH FACTORS IN THE PHARMACY'S ROLE IN THE OPIOID CRISIS

Due to a confluence of systemic, social, and medical factors, the opioid crisis remains a serious public health emergency. Overprescription, poor pain management, and a lack of patient education are some of the health-related factors that have contributed most to the rise in opioid addiction and misuse.

Pharmacists are in a unique position to address these factors through interventions that focus on harm reduction, education, and prevention because they are dependable and approachable healthcare professionals.

I. Effects of Overprescription Drugs

One of the main causes of the opioid epidemic has been the extensive overprescription of opioids. Opioids were first prescribed to treat acute and chronic pain, but their long-term risks—such as dependence and addiction—were frequently overlooked. Many patients were started on high-dose or prolonged courses of opioids, which was made worse by the absence of standardized guidelines for opioid prescribing in previous decades. Pharmacists are essential in reducing these risks because they make sure that evidence-based prescribing guidelines are followed. In order to assess whether opioid prescriptions are appropriate, they can collaborate with prescribers and, when practical, offer substitutes. For instance, pharmacists can suggest multimodal pain management strategies such as cognitive-behavioural therapy, physical therapy, or non-opioid analgesics (Dowell et al., 2016). Additionally, pharmacists can spot high-risk prescribing patterns and take appropriate action by using tools like Prescription Drug Monitoring Programs (PDMPs).

II. Education of Patients and Risk Reduction

Many patients who are prescribed opioids are not fully aware of the risks associated with them, such as the possibility of addiction, overdose, and drug interactions. As frontline educators, pharmacists give patients vital information about the safe and efficient use of opioids. This covers how to take the medication as prescribed, how to avoid using alcohol or other sedatives at the same time, and how to spot overdose or dependence symptoms. The availability of opioids for diversion and abuse can be decreased by pharmacists' promotion of appropriate disposal practices for unused medications. The quantity of unused opioids in households has been successfully decreased by pharmacist-led public education initiatives like National Prescription Drug Take Back Day (DEA, 2022).

III. Harm Reduction Strategies

Pharmacists are essential to harm reduction initiatives in addition to prevention and education. The distribution of naloxone, a drug that can quickly reverse the effects of an opioid overdose, is one of the most effective interventions. Many jurisdictions allow pharmacists to dispense naloxone without a prescription, increasing accessibility for overdose victims and their loved ones. Additionally, pharmacists train community members on naloxone administration, making them ready to respond in an emergency. Additionally, pharmacists participate in programs that assist patients with opioid use disorder (OUD). For instance, they might work with medical teams to oversee medication-assisted treatment (MAT) programs, which help people with cravings and withdrawal symptoms by using drugs like methadone or buprenorphine (SAMHSA, 2021). By taking part in these programs, pharmacists help people with OUD stabilize and recover over the long term.

IV. Resolving Health Inequalities

Inequalities in health care access to addiction treatment and pain management have made the opioid crisis worse. People living in underserved and rural areas frequently encounter major obstacles

to receiving care, such as restricted access to medical professionals and addiction treatment programs. In these communities, pharmacists are frequently the most approachable medical professionals, filling in care gaps with services like mobile naloxone distribution, tele pharmacy consultations, and community outreach initiatives (Bach et al., 2020).

V. The Path Forward

The opioid crisis calls for a multipronged strategy that includes harm reduction, education, prevention, and fair access to care. Because of their knowledge of medication administration and ease of access, pharmacists are in a good position to spearhead initiatives to prevent opioid abuse. The burden of opioid-related harm can be considerably decreased by pharmacists through proactive patient engagement, teamwork, and involvement in public health campaigns.

PHARMACIST PATIENT CARE PROCESS

Effective opioid misuse and accidental overdose prevention begins with systematically identifying patients at risk. Screening for opioid misuse risk is a critical first step when initiating opioid therapy, allowing healthcare providers to take proactive measures tailored to individual patient needs. This process can be integrated into the broader framework of the Pharmacist Patient Care Process (PPCP), which ensures a comprehensive and structured approach to care.

Collect

The initial phase involves gathering detailed patient information to establish a foundation for care. Pharmacists and healthcare providers collect data from various sources, including the patient's medical history, current medications, and any prior history of substance misuse or addiction. Additional factors such as mental health conditions, family history of substance abuse, and social determinants of health (e.g., access to resources or housing instability) are also important to assess. Screening tools like the Opioid Risk Tool (ORT) or the Screener and Opioid Assessment for Patients with Pain (SOAPP) may be used to identify patients at heightened risk for opioid misuse or overdose (Cipolle et al., 2012).

Assess

Once screening data is collected, the next step is to evaluate the patient's risk profile. This involves analysing the screening results alongside clinical judgment to categorize the patient's level of risk for opioid misuse, dependence, or overdose. For example, a patient with a personal or family history of substance misuse or mental health conditions may be classified as high risk. Additionally, pharmacological considerations, such as drug-drug interactions and the potential for tolerance, are evaluated during this phase.

Plan

Based on the findings from the assessment phase, a tailored care plan is developed to mitigate risks and promote safe opioid use. The plan may include a combination of patient education, closer monitoring, and referrals to additional resources or support programs. For high-risk patients, the plan might involve integrating alternative pain management strategies, such as non-opioid medications, physical therapy, or behavioural interventions. Patients may also be educated on the availability and proper use of naloxone to reverse opioid overdoses, if needed.




Figure 1. Process of pharmacist patient care

Implement

During this phase, the interventions outlined in the care plan are carried out. Pharmacists provide counselling on safe opioid use, emphasizing adherence to prescribed dosages, avoiding the use of alcohol or other depressants, and recognizing signs of overdose. For patients at higher risk, pharmacists may facilitate access to naloxone and provide hands-on training for its administration. Other strategies might include regular medication reviews to ensure ongoing appropriateness of opioid therapy and collaboration with other healthcare professionals to manage complex cases (Hepler & Strand, 1990).

Follow-Up: Monitor and Evaluate

The final phase involves ongoing monitoring to assess the patient's progress and the effectiveness of the interventions. Follow-up efforts may include periodic check-ins to evaluate adherence to the treatment plan, the resolution of pain management goals, and the emergence of any new risks or complications. Monitoring tools, such as Prescription Drug Monitoring Programs (PDMPs), can help track prescription activity and detect potential misuse. Adjustments to the care plan are made as needed to ensure continued patient safety and improved outcomes (Joint Commission of Pharmacy Practitioners [JCPP], 2014).

CHALLENGES

As a major threat to global health, the opioid epidemic necessitates a multidimensional and cooperative strategy to lessen its effects. Lack of professional development, cultural stigma, regulatory framework gaps, poor education, and scarce resources are some of the main obstacles to combating opioid abuse and addiction. With a focus on their importance and

consequences for healthcare systems, this review attempts to examine these issues in depth.

1. Education & Literacy

A significant factor contributing to opioid misuse is the lack of awareness and understanding of their associated risks. Addressing this issue requires targeted education for both healthcare professionals and the public. Public initiatives could include school curricula, community awareness campaigns, and drug information centers to highlight the dangers of opioid misuse, promote safe practices, and provide details about treatment options. Simultaneously, healthcare providers and pharmacists should receive training in opioid stewardship, alternative pain management strategies, and early detection of misuse. Enhanced education and training can empower individuals to make informed choices about pain management while reducing the stigma surrounding opioid addiction and treatment (Volkow and McLellan, 2016).

2. Regulatory Framework

Regulations on opioid use and distribution are essential to preventing misuse while ensuring that patients with legitimate pain management needs retain access to necessary treatments. Governments and regulatory bodies should implement robust policies, such as limiting overprescription, enforcing prescription monitoring programs (PDMPs) to identify high-risk prescribing practices and vulnerable patients, and requiring pharmacist oversight during opioid dispensing. International cooperation is also vital to regulate opioid distribution and combat illicit trafficking and misuse on a global scale (Dowell, Haegerich and Chou, 2016).




Figure 2. Key factors influencing opioid misuse prevention strategies

3. Cultural Beliefs & Social Stigma

Cultural attitudes and the stigma surrounding opioid addiction pose significant challenges to treatment and prevention efforts. Addiction is often misperceived as a moral weakness rather than a medical condition, resulting in discrimination and delays in seeking care. To overcome these barriers, public campaigns should focus on reshaping misconceptions, highlighting that opioid misuse is a health issue that requires empathy and evidence-based interventions. Engaging with community leaders and organizations can further ensure that initiatives are culturally sensitive and effectively reduce stigma at the local level (Livingston et al., 2012).

4. Professional Development

Continuous professional development is vital for healthcare professionals to remain informed about best practices in opioid stewardship and treatment. Ongoing training programs should focus on updated guidelines, alternative pain management approaches, and harm reduction techniques. Interdisciplinary collaboration among pharmacists, physicians, and addiction

specialists can enhance care quality and improve patient outcomes. Additionally, global knowledge-sharing initiatives enable the exchange of effective strategies and innovations to address the opioid crisis more comprehensively (Stringer et al., 2019).

5. Resources

Effective opioid stewardship relies on the availability of adequate resources, including skilled personnel, robust infrastructure, and sufficient funding. Expanding the healthcare workforce, particularly in underserved areas, is crucial to ensure education, monitoring, and treatment services are accessible. Building specialized clinics, rehabilitation centers, and drug information hubs can further support prevention and recovery efforts. Additionally, increased investments in research are essential to develop safer pain management alternatives and deepen the understanding of addiction, paving the way for sustainable solutions (Bach and Dugan, 2020).

OPIOID STEWARDSHIP STRATEGIES

The picture shows a thorough strategy for controlling opioid use and reducing related risks. It highlights an interrelated set of tactics meant to enhance patient outcomes, deal with abuse, and

promote safe practices. A thorough explanation of each element is provided below:



Figure 3. Strategies for preventing opioid misuse

1. Appropriate Prescription

Ensuring that opioids are prescribed only when truly necessary, at an appropriate dosage, and for a suitable duration is essential for minimizing risks. This approach helps reduce the likelihood of dependence, overdose, and misuse. To support healthcare providers in making informed decisions about opioid prescriptions, guidelines like those from the Centres for Disease Control and Prevention (CDC) offer valuable recommendations on when and how to prescribe these medications responsibly (Dowell, Haegerich, & Chou, 2016).

2. Monitoring Programs

The purpose of Prescription Drug Monitoring Programs (PDMPs) is to monitor the prescription and use of opioids. They are especially important in spotting and stopping improper prescription practices and "doctor shopping." Healthcare professionals can improve the safe and responsible use of opioids by regularly reviewing patient records and incorporating these monitoring tools into clinical workflows (Prescription Drug Monitoring Program Training and Technical Assistance Center, n.d.).

3. Non-Opioid Management

To effectively manage pain and lessen dependency on opioids, it is essential to investigate non-opioid medications like acetaminophen or NSAIDs, physical therapy, cognitive-behavioural therapy, and other alternative therapies. By collaborating between therapists and pain specialists, a multidisciplinary approach guarantees patients comprehensive and customized care, fostering safer and more long-lasting pain management techniques (Gordon et al., 2005).

4. Addressing Stigma

It is crucial to address prejudices and unfavourable views about opioid use and dependent in order to create a welcoming atmosphere where people can seek treatment without worrying about prejudice or condemnation. Awareness drives to lessen stigma and inform communities about dependency as a medical condition, as well as educational courses for healthcare professionals to foster empathy and understanding, can help achieve this (National Institute on Drug Abuse, 2021).

5. Dose Tapering

Encouragement of safe medication practices requires lowering opioid dosages gradually for patients who are no longer in need of them or who are at risk of becoming dependent. This method reduces withdrawal symptoms and eliminates the dangers of stopping suddenly. In order to ensure a safe and successful transition, implementation entails developing individualized

tapering plans that are specific to each person's requirements and closely monitored by medical professionals (Mayo Clinic, 2020).

6. Safe Disposal

To stop abuse and lessen the supply of opioids for non-medical use, it is essential to properly dispose of any unused or expired medications. Initiatives like encouraging medication take-back programs, setting up secure disposal kiosks, and teaching the public safe at-home disposal techniques can all help achieve this. These initiatives aid in ensuring that opioids are disposed of properly and do not endanger other people (U.S. Food and Drug Administration, 2021).

7. Patient Education

In order to encourage informed decision-making and early misuse detection, it is essential to educate patients about the advantages and disadvantages of opioid therapy, the symptoms of addiction, and available alternative treatments. This can be accomplished through providing patients with easily understood educational materials and conducting in-depth counselling during clinical visits, guaranteeing that patients have the information necessary to make decisions about their care that are both safe and efficient (Substance Abuse and Mental Health Services Administration, 2021).

8. Rehabilitation Services

Improving recovery outcomes and lowering relapse rates for people with opioid use disorder requires offering them all-encompassing support through therapy, psychological counselling, and medication-assisted treatment (MAT). This strategy addresses the psychological and physiological components of addiction by providing access to evidence-based treatments like buprenorphine or methadone in conjunction with behavioural therapies. People who use these integrated care models have a better chance of long-term recovery (World Health Organization, 2009).

This interrelated framework emphasizes the need for a comprehensive, patient-centred strategy that includes early detection, therapeutic intervention, and recovery services in order to effectively manage opioid use.

FUTURE PERSPECTIVE

1. Advanced Prescription Monitoring

Prescription drug monitoring programs (PDMPs) powered by AI are used to identify trends in misuse and alert pharmacists instantly. PDMPs and pharmacy software can be seamlessly integrated to provide automated patient risk scoring (Smith et al., 2022).

2. Individualized Patient Guidance

The use of AI-powered platforms to offer individualized education on opioid abuse based on a patient's social and medical history and Use of augmented reality (AR) and virtual reality (VR) for fully immersive counselling on alternative pain management methods and opioid risks. Culturally aware and multilingual teaching materials to reach a wide range of demographics (Jones et al., 2021).

3. Collaborative Care Models

Pharmacists can enhance outcomes by collaborating closely with multidisciplinary healthcare teams, including physicians, pain specialists, and behavioural health providers. By working together, they can ensure that pain management plans are holistic and incorporate non-opioid alternatives where appropriate. Research highlights that multidisciplinary care improves patient outcomes and reduces opioid dependency (Johnson et al., 2020).

4. Expanded Naloxone Access

One essential element of preventing opioid misuse is increasing access to naloxone, the medication that reverses an opioid overdose. Pharmacists can take the lead in distributing naloxone and providing instruction on how to use it. Future initiatives might incorporate community training sessions and over-the-counter naloxone access, as these have been demonstrated to lower the number of opioid overdose deaths (Davis et al., 2021).

5. Artificial Intelligence (AI) Integration

By examining prescription records and patient histories, artificial intelligence could potentially be used to help pharmacists identify patients who may be at risk of abusing opioids. AI systems might also track adherence trends and recommend non-opioid substitutes. AI integration in pharmacy practice has the potential to improve decision-making and stop opioid abuse before it starts (Gao et al., 2022).

6. Tele pharmacy Services

Tele pharmacy may offer an essential vehicle for pharmacists to assist opioid users via virtual consultations as telehealth technology continues to grow. This type of program can be particularly helpful in underserved or rural areas. Future tele pharmacy projects could involve tracking opioid usage, providing advice on how to properly dispose of medications, and making sure tapering schedules are followed. According to studies, tele pharmacy can increase patient engagement and healthcare access (Chen et al., 2020).

CONCLUSION

Pharmacist-led interventions are crucial in addressing opioid misuse and overdose. Expanding pharmacists' roles in community and clinical settings can prevent misuse, improve patient education, and enhance medication management practices. Pharmacists are well-equipped to monitor prescription patterns, educate patients about opioid risks, and provide safe usage and disposal counseling. Empowering pharmacists through policies and training programs can identify early signs of misuse and intervene promptly. Incorporating pharmacist-driven initiatives like enhanced prescription monitoring, naloxone distribution, and collaboration with multidisciplinary teams can significantly reduce opioid dependence and overdose. Legislative measures, such as expanded access to naloxone and prescription drug monitoring systems, can further support pharmacist-led strategies. This proactive approach not only addresses immediate opioid misuse concerns but also supports long-term efforts to reduce societal impacts of addiction and overdose.

REFERENCES

- Adams, N., Ott, C.A., Mullen, C.J. and Wang, Y., 2024. An Integrative Review of Opioid Stewardship: Optimizing Patient Care and Safety with a Multidisciplinary Approach. *Nursing: Research and Reviews*, pp.173-200.
- Ardeljan, L.D., Waldfogel, J.M., Bicket, M.C., Hunsberger, J.B., Vecchione, T.M., Arwood, N., Eid, A., Hatfield, L.A., McNamara, L., Duncan, R. and Nesbit, T., 2020. Current state of opioid stewardship. *American journal of health-system pharmacy*, 77(8), pp.636-643.
- Bach, A. T., Larson, C. M., & Dugan, B. D. (2020). Addressing opioid misuse in rural America: The role of community pharmacists. *Journal of the American Pharmacists Association*, 60(3), 453-459. <https://doi.org/10.1016/j.japh.2019.10.010>
- Bach, A.T. and Dugan, B.D., 2020. Addressing opioid misuse in rural America: The role of community pharmacists. *Journal of the American Pharmacists Association*, 60(3), pp.453-459. Available at: <https://doi.org/10.1016/j.japh.2019.10.010>
- Chen, C.L., Manogaran, R. and Rummans, T.A., 2020. Telepharmacy: A transformative tool in opioid management. *American Journal of Health-System Pharmacy*, 77(11), pp.823-831.
- Cid, A., Ng, A. and Ip, V., 2023. Addressing the Opioid Crisis—The Need for a Pain Management Intervention in Community Pharmacies in Canada: A Narrative Review. *Pharmacy*, 11(2), p.71.
- Cipolle, R. J., Strand, L. M., & Morley, P. C. (2012). *Pharmaceutical care practice: The patient-centered approach to medication management services* (3rd ed.). McGraw-Hill Education.
- Davis, C.S. and Carr, D., 2021. Expanding naloxone access: The role of pharmacists in opioid overdose prevention. *Journal of the American Pharmacists Association*, 61(4), pp.493-499.
- Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC guideline for prescribing opioids for chronic pain — United States, 2016. *JAMA*, 315(15), 1624-1645. <https://doi.org/10.1001/jama.2016.1464>
- Drug Enforcement Administration. (2022). National Prescription Drug Take Back Day. Drug Enforcement Administration. <https://www.dea.gov>
- Ducharme, L.J., Wiley, T.R., Zur, J.B., Vizcaino-Riveros, J.A. and Martin, L., 2024. A review of implementation research funded by the National Institute on Drug Abuse, 2007-2023: Progress and opportunities. *Journal of Substance Use and Addiction Treatment*, p.209489.
- Friedman, J., 2024. Looking Back on COVID-19 and the Evolving Drug Overdose Crisis: Updated Trends Through 2022. *American Journal of Public Health*, 114(3), pp.280-283.
- Frimerman, L., 2020. Opioid-related hedonic feelings, opioid craving, and prescription opioid misuse among patients with chronic pain prescribed long term opioid therapy. McGill University (Canada).
- Gao, Z., Li, M. and Lee, D., 2022. Artificial intelligence in opioid prescription monitoring and patient care. *Journal of Medical Informatics*, 29(6), pp.245-253.
- Gordon, D.B., Dahl, J.L., Miasowski, C., McCarberg, B., Todd, K.H., Paice, J.A., Lipman, A.G., Bookbinder, M., Sanders, S.H., Turk, D.C. and Carr, D.B., 2005. American pain society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force. *Archives of internal medicine*, 165(14), pp.1574-1580.
- Hepler, C. D., & Strand, L. M. (1990). Opportunities and responsibilities in pharmaceutical care. *American Journal of Hospital Pharmacy*, 47(3), 533-543.
- Hughes, T.D., Nowak, J., Sottung, E., Mustafa, A. and Lingehtetty, G., 2024. Empowering Pharmacists: Strategies for Addressing the Opioid Crisis through a Public Health Lens. *Pharmacy*, 12(3), p.82.
- Johnson, M.R. and Chen, D.M., 2020. Multidisciplinary care in the management of chronic pain: A strategy to reduce opioid misuse. *Pain Medicine*, 21(2), pp.309-315.
- Joint Commission of Pharmacy Practitioners. (2014). *Pharmacists' patient care process*. Joint Commission of Pharmacy Practitioners. <https://www.jcpp.net>

- Jones, L.A., Spurlock, K. and Taylor, R.S., 2021. Improving patient education and opioid safety in community pharmacy. *The Journal of Clinical Pharmacology*, 61(4), pp.550-558.
- Livingston, J.D., et al., 2012. The effectiveness of interventions for reducing stigma related to substance use disorders: A systematic review. *Addiction*, 107(1), pp.39-50. Available at: <https://doi.org/10.1111/j.1360-0443.2011.03632.x>
- Mayo Clinic, 2020. Guidelines for opioid tapering. Mayo Clinic. Available at: <https://www.mayoclinic.org>
- National Institute on Drug Abuse, 2021. Stigma and addiction. National Institute on Drug Abuse. Available at: <https://www.nida.nih.gov>
- Offu, O.F., Visram, S., Rathbone, A.P. and Lindsey, L., 2024. Factors influencing pharmacists' roles in preventing prescription and over-the-counter opioid misuse: a systematic review and narrative synthesis. *International Journal of Pharmacy Practice*, 32(2), pp.133-145.
- Prescription Drug Monitoring Program Training and Technical Assistance Center, n.d. Prescription Drug Monitoring Programs: Resources and Support. Available at: <https://www.pdmpassist.org>
- Smith, C.E., Williams, R. and Roberts, J., 2022. Integrating prescription drug monitoring programs into pharmacy practice. *Journal of Pharmaceutical Policy and Practice*, 14(1), p.17.
- Stringer, K.L., et al., 2019. A global perspective on professional development in addressing the opioid epidemic. *Pharmacy*, 7(3), p.106. Available at: <https://doi.org/10.3390/pharmacy7030106>
- Substance Abuse and Mental Health Services Administration, 2021. Patient education resources. Available at: <https://www.samhsa.gov>
- Substance Abuse and Mental Health Services Administration. (2021). Medication-assisted treatment (MAT). Substance Abuse and Mental Health Services Administration. <https://www.samhsa.gov>
- U.S. Food and Drug Administration, 2021. Medication disposal: How to dispose of unused medicines. U.S. Food and Drug Administration. Available at: <https://www.fda.gov>
- Volkow, N. D., Jones, E. B., Einstein, E. B., & Wargo, E. M. (2019). Prevention and treatment of opioid misuse and addiction: A review. *JAMA Psychiatry*, 76(2), 208-216. <https://doi.org/10.1001/jamapsychiatry.2018.3125>
- Volkow, N.D. and McLellan, A.T., 2016. The opioid epidemic: A need for increased education and awareness. *New England Journal of Medicine*, 374(2), pp.125-135. Available at: <https://doi.org/10.1056/NEJMr1511480>
- World Health Organization, 2009. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. World Health Organization. Available at: <https://www.who.int>